Thomas Steyer’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Thomas Steyer’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,055,000	Closed	-$403M	–	165
2025 Q1	$403M	Buy	+3,055,000	New	+$381M	1.93%	20
2024 Q2	–	Sell	-231,000	Closed	-$16M	–	188
2024 Q1	$16M	Buy	+231,000	New	+$15.9M	0.07%	82
2019 Q1	–	Sell	-250,000	Closed	-$2.85M	–	105
2018 Q4	$2.85M	Hold	250,000	–	–	0.02%	93
2018 Q3	$5.42M	Buy	+250,000	New	+$5.23M	0.03%	88

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Thomas Steyer's ITCI Position: Q2 2025 in Review

Thomas Steyer sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,055,000 shares — an estimated $403M sold.

Thomas Steyer first reported a position in ITCI in Q3 2018 and held it in 4 quarters. The position peaked at $403M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Thomas Steyer reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Thomas Steyer sold 3,055,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $403M.
Thomas Steyer first reported a position in Intra-Cellular Therapies Inc. in Q3 2018 and held it in 4 quarters.
Thomas Steyer's Intra-Cellular Therapies Inc. position peaked at $403M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Farallon Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.